Search Results - "Macabéo, Bérengère"

Cost-Effectiveness of Increasing Influenza Vaccination Coverage in Adults with Type 2 Diabetes in Turkey by Akın, Levent, Macabéo, Bérengère, Caliskan, Zafer, Altinel, Serdar, Satman, Ilhan

“…In Turkey, the prevalence of diabetes is high but the influenza vaccination coverage rate (VCR) is low (9.1% in 2014), despite vaccination being recommended…”
Get full text

Annual public health and economic benefits of seasonal influenza vaccination: a European estimate by Preaud, Emmanuelle, Durand, Laure, Macabeo, Bérengère, Farkas, Norbert, Sloesen, Brigitte, Palache, Abraham, Shupo, Francis, Samson, Sandrine I

“…Vaccination is currently the most effective means of preventing influenza infection. Yet evidence of vaccine performance, and the impact and value of seasonal…”
Get full text

Comparative efficacy and safety of targeted therapies for BRAF-mutant unresectable or metastatic melanoma: Results from a systematic literature review and a network meta-analysis by Corrie, Pippa, Meyer, Nicolas, Berardi, Rossana, Guidoboni, Massimo, Schlueter, Maximilian, Kolovos, Spyros, Macabeo, Bérengère, Trouiller, Jean-Baptiste, Laramée, Philippe

“…•Combination therapies for metastatic melanoma are more efficacious than monotherapies.•Encorafenib + binimetinib showed favourable efficacy compared to other…”
Get full text

Response to ‘considerations regarding a network meta-analysis of targeted therapies for BRAF mutant unresectable or metastatic melanoma’ by Corrie, Pippa, Meyer, Nicolas, Berardi, Rossana, Guidoboni, Massimo, Schlueter, Max, Kolovos, Spyros, Macabeo, Bérengère, Trouiller, Jean-Baptiste, Laramée, Philippe

Get full text

Cost-effectiveness of encorafenib with binimetinib in unresectable or metastatic BRAF-mutant melanoma by Trouiller, Jean-Baptiste, Nikolaidis, Georgios F., Macabeo, Bérengère, Meyer, Nicolas, Gerlier, Laetitia, Schlueter, Max, Laramee, Philippe

“…Objective The objective of this study was to determine the cost-effectiveness of encorafenib with binimetinib (EncoBini) as compared to other targeted double…”
Get full text

Impact of quadrivalent influenza vaccine on public health and influenza-related costs in Australia by Jamotte, Aurélien, Chong, Chui Fung, Manton, Andrew, Macabeo, Bérengère, Toumi, Mondher

“…Annual trivalent influenza vaccines (TIV) containing three influenza strains (A/H1N1, A/H3N2, and one B) have been recommended for the prevention of influenza…”
Get full text

Cost-Effectiveness of Quadrivalent versus Trivalent Influenza Vaccine in the United States by de Boer, Pieter T., MSc, Crépey, Pascal, PhD, Pitman, Richard J., PhD, Macabeo, Bérengère, PharmD, Chit, Ayman, PhD, Postma, Maarten J., PhD

“…Abstract Background Designed to overcome influenza B mismatch, new quadrivalent influenza vaccines (QIVs) contain one additional B strain compared with…”
Get full text

A trivalent, inactivated influenza vaccine (Vaxigrip®): summary of almost 50 years of experience and more than 1.8 billion doses distributed in over 120 countries by Haugh, Margaret, Gresset-Bourgeois, Viviane, Macabeo, Bérengère, Woods, Anne, Samson, Sandrine I

“…Vaxigrip, a trivalent split-virion, inactivated vaccine available since 1968 has been in use longer than any other influenza vaccine. It is the most…”
Get full text

Economic evaluation of encorafenib with cetuximab in patients with BRAF V600E-mutant metastatic colorectal cancer in France: a cost-effectiveness analysis using data from the BEACON CRC randomised controlled trial by Trouiller, Jean-Baptiste, Macabeo, Bérengère, Poll, Andrew, Howard, Dan, Buckland, Andy, Sivignon, Marine, Clay, Emilie, Malka, David, Samalin, Emmanuelle, Toumi, Mondher, Laramée, Philippe

“…ObjectiveThe BEACON CRC randomised controlled trial (NCT02928224) in BRAF-mutant metastatic colorectal cancer (mCRC) patients showed improved overall survival…”
Get full text

The Acceptance of Indirect Treatment Comparison Methods in Oncology by Health Technology Assessment Agencies in England, France, Germany, Italy, and Spain by Macabeo, Bérengère, Rotrou, Théophile, Millier, Aurélie, François, Clément, Laramée, Philippe

“…Introduction Randomized controlled trials (RCTs) are the gold standard when comparing treatment effectiveness, and Health Technology Assessment (HTA) agencies…”
Get full text

Methods for Indirect Treatment Comparison: Results from a Systematic Literature Review by Macabeo, Bérengère, Quenéchdu, Arthur, Aballéa, Samuel, François, Clément, Boyer, Laurent, Laramée, Philippe

“…Health technology assessment (HTA) agencies express a clear preference for randomized controlled trials when assessing the comparative efficacy of two or more…”
Get full text

Public health impact and economic benefits of quadrivalent influenza vaccine in Latin America by Jamotte, Aurélien, Clay, Emilie, Macabeo, Bérengère, Caicedo, Andrès, Lopez, Juan Guillermo, Bricks, Lucia, Romero Prada, Martín, Marrugo, Rubén, Alfonso, Pamela, Moreno Arévalo, Brechla, Franco, Danilo, Garcia Diaz, Lourdes, Isaza de Molto, Yadira

“…Annual trivalent influenza vaccines (TIV) containing 2 A strains and one B lineage have been recommended for the prevention of influenza in most of Latin…”
Get full text

Access to innovative drugs and the National Reimbursement Drug List in China: Changing dynamics and future trends in pricing and reimbursement by Macabeo, Bérengère, Wilson, Liam, Xuan, Jianwei, Guo, Ruichen, Atanasov, Petar, Zheng, Linda, François, Clement, Laramée, Philippe

“…Background and objectives: Multiple reforms aimed at improving the Chinese population's health have been introduced in recent years, including several designed…”
Get full text

Medical and economic burden of influenza in the elderly population in central and eastern European countries by Kovács, Gábor, Kaló, Zoltán, Jahnz-Rozyk, Karina, Kyncl, Jan, Csohan, Agnes, Pistol, Adriana, Leleka, Mariya, Kipshakbaev, Rafail, Durand, Laure, Macabeo, Bérengère, Macabeo, Bérengère

“…Influenza affects 5-15% of the population during an epidemic. In Western Europe, vaccination of at-risk groups forms the cornerstone of influenza prevention…”
Get full text

Erratum to “Comparative efficacy and safety of targeted therapies for BRAF-mutant unresectable or metastatic melanoma: Results from a systematic literature review and a network meta-analysis” [Cancer Treat. Rev. 110 (2022) 102463] by Corrie, Pippa, Meyer, Nicolas, Berardi, Rossana, Guidoboni, Massimo, Schlueter, Maximilian, Kolovos, Spyros, Macabeo, Bérengère, Trouiller, Jean-Baptiste, Laramée, Philippe

Get full text